Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]DASA-23 PET in Intracranial Tumors
NCT03539731Phase 1Terminated
- Start
- Apr 2018
- Primary completion
- Dec 2022
- Countries
- 1
01
Overview
Phase 1, open-label trial of [18F]DASA-23 in intracranial neoplasm and glioblastoma (GBM) (4 arms). Primary endpoint: Change in [18F]DASA-23 PET scan signal at 1 week. Started Apr 2018; status: terminated.
02
Drugs
[18F]DASA-23
03
Conditions
intracranial neoplasmglioblastoma (GBM)
Beyond the preview
Go deeper on NCT03539731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03539731.